ALTI 1,20 $ - 500 Beiträge pro Seite

[V51]

Altair Nanotechnologies Receives Positive RenaZorb Animal Test
Results; RenaZorb, A Nanotechnology-Based Drug Candid
B: Altair Nanotechnologies Receives Positive RenaZorb Animal Test Results; RenaZ
rb, A Nanotechnology-Based Drug Candidate For Phosphate Control in Kidney Dialys
s Patients, Shows Phosphate Binding In Dogs And 5/6 Nephrectomized Rats

RENO, Nev., Jun 03, 2003 (PRIMEZONE via COMTEX) -- Altair Nanotechnologies,
Inc. (Nasdaq:ALTI) announced today that it has negotiated an agreement allowing
the disclosure of new animal testing data to interested third parties. Under the
previous non-disclosure agreement with the participating pharmaceutical company,
the animal testing data could not be disclosed. Altair developed three versions
of RenaZorb designated RenaZorb "A", "B", and "H". The study, completed in early
March 2003, was conducted in dogs and 5/6 nephrectomized rats utilizing three
versions of the drug candidate.

"The test results demonstrate indisputably that RenaZorb is effective in
lowering urinary phosphate in kidney impaired (5/6 nephrectomized) rats and in
healthy dogs," said Altair President Dr. Rudi E. Moerck. "This new collection of
test results provides potential licensees within the pharmaceutical industry a
more extensive set of in vivo data for evaluating RenaZorb`s phosphate binding
capabilities. "Additionally," continued Dr. Moerck, "the new test results have
provided Altair with important data that will permit further improvement of the
dosage form to enhance both the efficacy and potency of the drug candidate."

Altair continues active discussions pertaining to the licensing of RenaZorb with
numerous pharmaceutical companies. These companies are in various stages of
conducting due diligence of RenaZorb and management expects to receive their
response in the near future. Altair estimates that the current market for
phosphate binding drugs used for ESRD ranges from $400 to $600 million and could
potentially reach $1 billion with a cost effective drug presenting improved
dosing and patient compliance.

Non-calcium phosphate binders are indicated for patients who suffer from
end-stage renal disease (ESRD). These patients have difficulty in eliminating
dietary phosphate through their kidneys and elevated phosphate can cause bone
pain and spontaneous fractures. Currently, the only FDA approved phosphate
binder is Renagel(tm) (Genzyme). Shire Pharmaceuticals has received an
approvable letter from the FDA for Fosrenol(tm), which like RenaZorb, is a
lanthanum based pharmaceutical.

Altair Nanotechnologies, Inc.

Nanotechnology is rapidly emerging as a unique industry sector. Altair
Nanotechnologies is positioning itself through product innovation within this
emerging industry to become a leading supplier of nanomaterials and technology
worldwide. Altair owns a proprietary technology for making nanocrystalline
materials of unique quality both economically and in large quantities. The
company is currently developing special nanomaterials with potential
applications in pharmaceuticals, fuel cells, solar cells, advanced energy
storage devices, thermal spray coatings, catalysts, paints and environmental
remediation. For additional information on Altair`s nanoparticle materials,
visit www.altairnano.com.

Forward-Looking Statements

This release may contain forward-looking statements as well as historical
information. Forward-looking statements, which are included in accordance with
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995, may involve risks, uncertainties and other factors that may cause the
company`s actual and future results to be materially different than suggested by

the forward-looking statements in this release. These risks and uncertainties
include, without limitation, the successful testing, FDA approval and
commercialization of RenaZorb, the company may be unable to attract or form
relationships with pharmaceutical companies, or have the funds necessary to
development additional products or create product opportunities within the
pharmaceutical industry, in addition to other risks identified in the company`s
most recent Annual Report on Form 10-K, as filed with the SEC. Such
forward-looking statements speak only as of the date of this release. The
company expressly disclaims any obligation to update or revise any
forward-looking statements found herein to reflect any changes in company
expectations or results or any change in events.

The Altair Nanotechnologies Inc. company logo can be found at:
http://media.primezone.com/prs/single/?pkgid=511


By Staff
CONTACT: Altair Nanotechnologies
Tracy LaFollette
[phone]
[e-mail]

Investor Relation Resources, LLC
Marty Tullio
[phone]
[e-mail]


(C) 2003 PRIMEZONE, All rights reserved.

-0-


INDUSTRY KEYWORD: Diversified Technology
SUBJECT CODE: PHARMACEUTICALS
CHEMICALS
Company Announcement

*** end of story ***

[Musikpalette]

WKN 902675
man geht die im Amiland ab, schlafen hier noch alle?
Gruß
MP

[Ariminios]

nee, aber ich Vollidiot habe im pre market zu 96 cents verkauft, weil ich die news nochnicht gesehen hatte!

Scheisse!